Recent Updates — NGEN
NervGen Pharma Corp. filed an amended Form 6-K to restate its unaudited condensed consolidated interim financial statements for the three and six months ended June 30, 2026, as well as its annual report for the year ended December 31, 2025. The restatement corrects material misstatements in warrant derivative liabilities, unrealized gains or losses on warrant derivatives, stock-based compensation expense, share issuance costs, and accumulated deficit. These errors stemmed from miscalculations of annualized volatility inputs used in Black-Scholes-Merton valuation models for options and warrants, as well as the incorrect classification of share issuance costs. The company identified material weaknesses in its internal control over financial reporting regarding valuation methodology documentation and segregation of duties within finance personnel. While the adjustments do not impact cash flows or liquidity, they significantly alter reported operating expenses and net income/loss figures. NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing neuroreparative therapeutics for spinal cord injury.
On September 25, 2026, NervGen Pharma Corp.'s audit committee concluded that previously issued audited financial statements for years ended December 31, 2024 and 2025, as well as unaudited interim information for the quarter ended June 30, 2026, should no longer be relied upon. The company identified non-cash valuation errors in accounting for stock options and derivative warrant liabilities, which reduced previously reported stock-based compensation expense and warrant liabilities. NervGen intends to restate these affected financials via amendments to its Form 40-F and Form 6-K filings. These adjustments do not impact the company's cash position, cash flow, or liquidity. The company operates in the biopharmaceutical industry, focusing on the development of gene therapies.
NervGen Pharma Corp. reported unaudited financial results for the six months ended June 30, 2026, showing a net loss of CA$30.9 million compared to CA$13.1 million in the prior year period. Cash and cash equivalents increased significantly to CA$86.8 million from CA$22.1 million at year-end 2025, driven by gross proceeds of CA$82.9 million (US$60.0 million) from an underwritten public offering closed on May 22, 2026. The company also initiated a new ATM equity program on Nasdaq in July 2026 following the termination of its previous TSX Venture Exchange program. Operating expenses rose to CA$19.7 million, with research and development spending nearly doubling to CA$12.8 million as the company prepares for Phase 3 clinical trials of its lead candidate NVG-291 for spinal cord injury. NervGen Pharma Corp. operates in the biotechnology industry, focusing on the discovery and development of neuroreparative therapeutics.
NervGen Pharma Corp. entered into a Sales Agreement with Leerink Partners LLC on July 2, 2026. The company operates in the biotechnology industry and develops therapies for neurodegenerative diseases.